# 1st Gen Model Regeneron Pharmaceuticals, Inc. Pharmaceutical preparations
at 22-aug-2017
REGN
Model's trade recommendations 5.63% Return for period
-1.93% Annual return
$49.93B Market Cap
β 1.66
REGN
Model (following trade recommendations)REGN
Underlying stockS&P 500
Index- BUY Analysts consensus recommendation
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for Regeneron Pharmaceuticals, Inc. (REGN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 22, 2015.
Market data for REGN model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 95M |
| P/E | 44.15 |
| Shares Outstanding | 106M |
| % Held by Insiders | 10.40% |
| % Held by Institutions | 67.16% |
| EPS (last reported FY) | $8.26 |
| EPS (last reported Q) | $3.88 |
| EPS, estimated (last reported Q) | $2.67 |
| Total revenues | $5 B |
| Net income | $1 B |